Soligenix shares surge 106.40% intraday after completing Phase 2a proof of concept study for SGX945 in Behcet's Disease.

Soligenix, Inc. surged 106.40% intraday, with the company announcing the completion of its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behcet's Disease. The study demonstrated biological efficacy, supporting the advancement of SGX945 in this difficult-to-treat orphan disease. The positive results from the clinical trial indicate potential anti-tumor activity and safety, which aligns with the significant increase in the stock price.